Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels

Greenman, Yona; Tordjman, Karen; Stern, Naftali

doi:10.1046/j.1365-2265.1998.00403.x

Cited by 206 publications

(190 citation statements)

References 23 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…Prolactinomas producing high levels of prolactin are typically associated with weight gain 4. In addition, a study in obese women found that increased BMI and VAT are associated with an increased prolactin secretion rate 8.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study

Therkelsen

Abraham

Pedley

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundProlactin is an anterior pituitary hormone that may modulate the adverse effects of obesity. Prolactin has been associated with cardiovascular disease mortality, but less is known about whether prolactin predicts incidence of cardiovascular disease risk factors.Methods and ResultsOur sample (n=3232, mean age 40.4 years, 52.1% women) was drawn from Framingham Heart Study participants who attended 2 examinations an average of 6.1 years apart. After excluding those with elevated prolactin (>30 mg/dL for women, >20 mg/dL for men), multivariable‐adjusted regressions modeled the associations between baseline prolactin and changes in cardiovascular disease risk factors. Models were adjusted for age, sex, baseline value of the risk factor, smoking status, hormone replacement therapy, and menopausal status and additionally for body mass index. Mean prolactin levels were 11.9 mg/dL (SD 5.2) in women and 8.0 mg/dL (SD 2.9) in men. No associations were observed for change in weight, body composition, total cholesterol, triglycerides, or fasting glucose. In women, for example, for each 5‐mg/dL increment in prolactin, odds of incident hypercholesterolemia were 1.06, which was not significant (95% CI 0.91–1.23, P=0.46). Some exceptions were of note. In women, for each 5‐mg/dL increment in prolactin, we observed increased odds of low high‐density lipoprotein cholesterol at follow‐up (odds ratio 1.50, 95% CI 1.18–1.91, P=0.001) that persisted after adjustment for body mass index (P=0.001). In men, a 5‐mg/dL increment in prolactin was associated with increased odds of incident hypertension (odds ratio 1.61, 95% CI 1.18–2.20 P=0.002) and incident diabetes (odds ratio 1.70, 95% CI 1.04–2.78, P=0.03).ConclusionsProlactin is not associated with a comprehensive panel of incident cardiovascular disease risk factors. Measurement of circulating prolactin levels in the community likely does not provide substantial insight into cardiometabolic risk.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In rats, elevation of prolactin is associated with increased food intake and body weight 3. In humans with prolactinomas, weight gain is often a prominent feature and is reversible with prolactin‐lowering therapy 4. Other metabolic abnormalities seen in prolactinomas include insulin resistance and dyslipidemia 5.…”

Section: Introductionmentioning

confidence: 99%

Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study

Therkelsen

Abraham

Pedley

et al. 2016

JAHA

View full text Add to dashboard Cite

show abstract

“…[1][2][3] Subsequent weight loss after treatment with dopamine agonists has also been reported, 3,4 although this has been disputed in one study that showed weight gain after treatment. 5 We therefore undertook a retrospective study of 37 patients with prolactinoma (22 macroprolactinoma and 15 with microprolactinoma, defined by MRI scan of tumour size) and related body weight changes over 24 months to changes in serum and prolactin concentrations.…”

mentioning

confidence: 99%

Body weight and prolactinoma: a retrospective study

2003

View full text Add to dashboard Cite

“…Манифестация заболевания в описан-ном нами клиническом случае совпала с рез-ким снижением массы тела, что могло быть обусловлено развитием диэнцефальной ка-хексии вследствие вовлечения гипоталамуса в патологический процесс супраселлярно растущей опухолью. Напротив, в большин-стве случаев манифестация гиперпролакти-немии сопровождается повышением массы тела [14,15]. Убедительных клинико-лабора-торных данных за наличие гипокортицизма в описанном нами случае выявлено не было.…”

Section: Discussionunclassified

Cerebrospinal fluid rhinorrhoea in young women after 6.5 years of therapy giant prolactinoma with Cabergolin

et al. 2018

View full text Add to dashboard Cite

Cerebrospinal fluid (CSF) leak is a rare complication in of the prolactinomas treatment with dopamine agonists. In most cases CSF leak develops within the first three months of treatment starting. The article presents a rare clinical case – later development of CSF leak after pharmacological treatment of giant prolactinoma. Women 29 years with giant endo-supra-infra-laterasellar pituitary adenoma (8,7 cm in diameter), visual impairment, cachexia, secondary amenorrhea and prolactin level more than 2 million 200 thousand mU/l treated with cabergoline. On this background, complete regression of the tumor, recovery of visual function, body mass and normalization of prolactin level was marked. Nevertheless, after 6.5 years after beginning of cabergoline therapy CSF leak occured, which required endoscopic endonasal surgery with the plastic of a CSF fistula. All patients with large and giant prolactinomas which invade into skull base structures, receiving cabergoline even for a long time, should be aware of the possibility of such complications as CSF leak and, if necessary, should urgent appeals to the otolaryngologist and the neurosurgeon. In this case closure of skull base defect is a main tactics of treatment.

show abstract

Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels

Cited by 206 publications

References 23 publications

Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study

Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study

Body weight and prolactinoma: a retrospective study

Cerebrospinal fluid rhinorrhoea in young women after 6.5 years of therapy giant prolactinoma with Cabergolin

Contact Info

Product

Resources

About